0092184
print

Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation

CDASU 7
Example Reports
Negative
Positive

Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out drug exposure. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 8 mL urine with no additives or preservative to ARUP Standard Transport Tubes. (Min: 4 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

Methodology

Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

Interpretive Data

Flagging indicates a positive result; not that the result is abnormal.

Presumptive negative results for drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class.

For medical purposes only; not valid for forensic use.


Drugs/Drug Classes Screen
THC (Cannabinoids) Methodology: Immunoassay
Positive Cutoff: 50 ng/mL
Cocaine Methodology: Immunoassay
Positive Cutoff: 150 ng/mL
Opiates Methodology: Immunoassay
Positive Cutoff: 300 ng/mL
Oxycodone Methodology: Immunoassay
Positive Cutoff: 100 ng/mL
Phencyclidine Methodology: Immunoassay
Positive Cutoff: 25 ng/mL
Amphetamines Methodology: Immunoassay
Positive Cutoff: 300 ng/mL
MDMA (Ecstasy) Methodology: Immunoassay
Positive Cutoff: 500 ng/mL
Barbiturates Methodology: Immunoassay
Positive Cutoff: 200 ng/mL
Benzodiazepines Methodology: Immunoassay
Positive Cutoff: 200 ng/mL

Compliance Category

FDA

Note

If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.

Hotline History

N/A

CPT Codes

80307; if reflexed, add 80325; 80345; 80346; 80349; 80353; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0090386 Creatinine, Urine 2161-8
0090407 CDASU 7 Comments 77202-0
0092191 Amphetamines Screen, Urine 19261-7
0092192 Cocaine Screen, Urine 19359-9
0092193 Opiates Screen, Urine 19300-3
0092194 Phencyclidine Screen, Urine 19659-2
0092195 THC (Cannabinoids) Screen, Urine 19292-2
0092196 Barbiturates Screen, Urine 19270-8
0092197 Benzodiazepines Screen, Urine 14316-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Benzodiazepines, Urine
  • Cocaine, Urine
  • Creatinine, Urine
  • Pain Management
  • Phencyclidine, Urine
  • Marijuana, Urine
  • Opiates, Urine
  • Barbiturates, Urine
  • Amphetamines, Urine
Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation